

**Top 25 Products Ranked By Paid and Detailed FFS\* Drugs Summary Report By Dates of Service for  
the  
2nd Quarter 2009 (March, April and May)**

HICL	Rank	Claims	Paid	PUPM
QUETIAPINE FUMARATE	1	27,775	\$8,326,317	\$314.79
ARIPIRAZOLE	2	17,879	\$8,036,858	\$474.33
OLANZAPINE	3	7,449	\$4,074,820	\$579.95
MONTELUKAST SODIUM	4	28,630	\$3,453,370	\$120.82
FLUTICASONE PROPIONATE/SALMETEROL XINAFOATE	5	15,532	\$3,421,450	\$220.04
OXYCODONE HCL	6	11,808	\$3,376,541	\$324.28
TOPIRAMATE	7	12,430	\$2,991,034	\$250.01
DULOXETINE HCL	8	17,278	\$2,890,364	\$169.42
ANTIHEMOPHILIC FACTOR, HUM REC	9	113	\$2,617,479	\$29,876.49
BLOOD SUGAR DIAGNOSTIC	10	18,828	\$2,166,473	\$104.09
DIVALPROEX SODIUM	11	18,619	\$2,164,507	\$119.87
ATORVASTATIN CALCIUM	12	16,876	\$2,099,323	\$124.50
RISPERIDONE	13	19,815	\$1,971,472	\$102.89
INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG	14	11,080	\$1,892,719	\$169.45
ALBUTEROL SULFATE	15	47,514	\$1,886,118	\$43.09
VENLAFAXINE HCL	16	10,922	\$1,873,358	\$174.29
AMPHETAMINE ASPARTATE/AMPHETAMINE SULFATE/DEXTROAMPHETAMINE	17	12,490	\$1,825,314	\$147.60
METHYLPHENIDATE HCL	18	14,339	\$1,766,343	\$124.45
ZIPRASIDONE HCL	19	4,893	\$1,723,317	\$368.56
FENTANYL	20	3,615	\$1,511,147	\$448.31
SOMATROPIN	21	538	\$1,486,879	\$2,798.78
CLOPIDOGREL BISULFATE	22	9,364	\$1,464,806	\$156.66
PALIVIZUMAB	23	918	\$1,456,127	\$1,765.13
PALIPERIDONE	24	3,456	\$1,425,914	\$435.97
LAMOTRIGINE	25	11,986	\$1,338,246	\$114.90
<b>TOTALS</b>		<b>344,147</b>	<b>\$67,240,299</b>	<b>AVG \$200.78</b>

\* Previous reports contain MORx Claims. This quarter and all future quarters will contain Fee For Service claims only.